TG Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

Core Viewpoint - TG Therapeutics, Inc. will participate in the Goldman Sachs 46th Annual Global Healthcare Conference, highlighting its ongoing engagement with investors and the healthcare community [1]. Company Overview - TG Therapeutics is a fully integrated, commercial stage biopharmaceutical company focused on developing and commercializing novel treatments for B-cell diseases [3]. - The company has received FDA approval for BRIUMVI® (ublituximab-xiiy) for treating adult patients with relapsing forms of multiple sclerosis (RMS) [3]. - BRIUMVI has also been approved by the European Commission and the Medicines and Healthcare Products Regulatory Agency for treating adult patients with RMS in Europe and the United Kingdom [3]. Event Details - The fireside chat with Michael S. Weiss is scheduled for June 10, 2025, at 10:40 am ET during the conference held in Miami, FL [1]. - A live webcast of the fireside chat will be available on the company's website [2].